Influenza [strains A + B] (tetravalent, split virion) vaccine is under clinical development by Walvax Biotechnology and currently in Phase I for Influenzavirus B Infections. According to GlobalData, Phase I drugs for Influenzavirus B Infections have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Influenza [strains A + B] (tetravalent, split virion) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Influenza [strains A + B] (tetravalent, split virion) vaccine overview

Vaccine is under development for the prevention of influenza virus A and B infections. The vaccine candidate administered through intramuscular route. It is a 4-valent influenza virus split vaccine.

Walvax Biotechnology overview

Walvax Biotechnology (Walvax) is a biopharmaceutical company that develops, produces and markets bio-medical products including vaccines and blood products. The company’s products include the Haemophilus influenza vaccine for the prevention of infectious diseases such as meningitis. Walvax offers drugs for pneumonia, septicemia, cellulitis, arthritis and epiglottitis. It offers Group A and C meningococcal polysaccharide vaccines for preventing diseases such as cerebrospinal meningitis and septicemia and Group ACYW135 meningococcal polysaccharide vaccine to prevent meningococcal disease. The company markets its products through a distribution network in China. The company operates a research and development center in Kunming. Walvax is headquartered in Kunming, China.

For a complete picture of Influenza [strains A + B] (tetravalent, split virion) vaccine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.